Conclusions
CKD
INFLAMMATION, TYPE 2 DIABETES
In patients with type 2 diabetes and CKD, dapagliflozin increased hemoglobin/hematocrit and reduced ferritin and urinary MCP-1/Cr and IL-6/Cr, suggesting potentially important effects on iron metabolism and inflammation.